Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Stent showdown: which heart device heals faster?

NCT ID NCT02253108

Disease control Sponsor: Aarhus University Hospital Skejby Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two types of drug-coated stents (SYNERGY and BioMatrix NeoFlex) in 160 patients with coronary artery disease. Researchers use a special camera to check how well the stents heal inside the artery at 1 and 3 months after placement. The goal is to see which stent leads to better vessel healing.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
drug-eluting stent (device)
What this could lead to
If successful, this could show which stent helps blood vessels heal faster after heart procedures, potentially improving long-term outcomes.
What could go wrong
This is a small, early-phase study (160 participants) looking at healing markers, not long-term health benefits. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 160 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2014

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients \>18 years to be treated with one or more drug-eluting stents in a coronary artery at Aarhus University Hospital or Odense University Hospital Exclusion Criteria: * Age \<18 years * Do not wish to participate * Unable to provide written informed consent * Domicile outside Denmark * Do not speak Danish * Inclusion in the SORT-OUT VIII study * Inclusion in other stent studies * Expected survival \<1 year * Allergy to aspirin, clopidogrel, prasugrel or ticagrelor * Hypersensitivity to everolimus or biolimus * The operator wishes to use other DES * Reduced renal function; creatinine\> 120 mmol / L * Only bare metal stent (BMS) implantation * Only plain old balloon angioplasty (POBA)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Angina pectoris are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Angina Pectoris coronary artery disorder intermediate coronary syndrome myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Angina pectoris Coronary artery disease Myocardial infarction

Contacts and locations

Locations

  • Aarhus University Hospital, Skejby

    Aarhus, 8200, Denmark

  • Odense University Hospital

    Odense, 5000, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.